Organisation paid for research Program year 2024 Source: CMS Open Payments

Clinsearch

Neither a doctor nor a teaching hospital

Research payments

$123,119

22 payments

Through program year 2024, Clinsearch is reported as receiving $123,119 in research payments, across 22 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $17,684 1
2023 Research $3,643 3
2022 Research $282 2
2021 Research $894 2
2020 Research $64,582 6
2019 Research $36,035 8

Breakdown

Who paid Research payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $62,869 2 payments
  2. AstraZeneca UK Limited $33,471 2 payments
  3. AbbVie, Inc. $18,966 4 payments
  4. Allergan Inc. $4,831 10 payments
  5. GlaxoSmithKline, LLC. $2,643 2 payments
  6. E.R. Squibb & Sons, L.L.C. $340 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $96,339 4 payments
  2. 1698-302-007 Ph3 Extension Study (M21-489) $17,684 1 payment
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $2,725 6 payments
  4. A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval $2,643 2 payments
  5. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine $1,212 2 payments
  6. Safety and Efficacy of Oral Idebenone for Preventive Treatment of Migraine in Adult Migraine Patients $1,050 2 payments
  7. A Phase 3, Multicenter, Open-Label 52-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Chronic Or Episodic Migraine $761 1 payment
  8. Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants $232 1 payment
  9. Phase IIB Study - F3 24 wk $184 1 payment
  10. Phase IIB Study - F4 48 wk $156 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record